OBJECTIVES: 1) To assess if a translatability assessment (TA) conducted prior to a psychometric evaluation in PRO instrument development could predict items subsequently eliminated, and 2) to provide evidence to the extent to which a TA adds value to the translation and cultural adaptation of PRO instruments. The Youth Quality-of-Life Instrument-Weight module (YQOL-W) was chosen as a candidate questionnaire for this exercise. METHODS: A team of two linguists, blinded to the results of psychometric analyses and decisions on item reduction, conducted a TA on the 32-item pre-final version of the YQOL-W. Results were categorized into several types of issues. Items for possible deletion were identified and compared to the results of the item-reduction phase, using both qualitative and psychometric methods performed by the developer. RESULTS: During the item-reduction phase, 11 items were dropped; seven for qualitative reasons (items 10, 30, 31, 27-32) and four for weak factor loading (items 14, 16, 18, 19). Out of the 11 items dropped, TA identified nine problematic items (82%) and, among them, advised dropping five items (45.4%), either for redundancy with others (items 14, 19, 29, and 32) or inconsistency of construct with respect to concept (item 27). For item 28, TA recommended changing the original for semantic reasons. For items 10, 30, and 31, TA recommended using alternative wording for translation purposes but did not suggest changing the original. Finally, for items 16 and 18, TA recommended no changes. CONCLUSIONS: Our study showed that a translatability assessment can anticipate results of the item-reduction phase. Although more empirical studies are needed, we have demonstrated that the involvement of linguists in the early development phase could be a plus in detecting irrelevant or inappropriate items, and that a translatability assessment can be a useful step in PRO instrument development.
OBJECTIVES:
We explore whether comparative effectiveness research (CER) can in principle increase economic efficiency. METHODS: The definition and goals of CER are compared with the principles of economic theory. The implications when the two diverge are discussed. RESULTS: CER is frequently defined to include measurement of clinical benefits and harms. Economic efficiency on the other hand depends on individuals' preferences for the health technology under consideration relative to other health or non-health commodities (e.g., following the Grossman's utility model). The distinction is important because choosing the most clinically effective interventions as the end goal of CER may increase but fail to maximize societal welfare if other (e.g. non-health related) factors have greater marginal impact on patient or family utility. We present examples which may help explain why preferred care is not reimbursable and prescribed treatment not adhered to. In addition, economists define costs as the forgone value of alternative uses of resources; consequently, exclusion of costs from CER leads to underestimation of the NET value of effective interventions. CER will then fail to identify the intervention with the highest net value among alternatives with similar effectiveness and harms but different costs. Clinically superior interventions can also have lower net value than inexpensive (effective) alternatives. CONCLUSIONS: CER without account for patient preferences and economic costs can in some cases lead to rejecting interventions which although less effective than alternatives, may still have greater net societal value. The latter would reduce economic efficiency and lower societal welfare. Findings raise questions about the validity of two prevailing evaluation strategies: to conduct economic evaluations only if clinical superiority is first established and to use CER with priority for the evaluation of the most expensive interventions.
CE2 RECONCILING VARIATIONS IN PROPENSITY SCORE MATCHING (PSM) ALGORITHMS IN OBSERVATIONAL COMPARATIVE EFFECTIVENESS RESEARCH (OCER)
Borah BJ, Heien HC Mayo Clinic, Rochester, MN, USA OBJECTIVES: The OCER literature that evaluates comparative effectiveness of alternative medical intervention using existing databases has seen explosive growth in the use of PSM in recent years. However, different PSM algorithms (e.g., one-to-one, one-to-many, radius matching etc.) yield different estimates of the treatment effect. Moreover, matching-induced attrition in the original sample may change the target population for which the average treatment effect (ATE) was intended. This paper, using a real-world example, proposes a range of ATEs that results from different PSM algorithm instead of a single ATE that is typically reported in the literature. METHODS: Data for the empirical example come from health care claims and clinical information from electronic health records in a large U.S. hospital on patients that underwent hysterectomy with robotic (N=315) and abdominal (N=265) approaches. The ATE of interest is the predicted difference in 6-week all-cause costs starting from index surgery date.
Baseline characteristics including age, race, insurance type, BMI, comorbidities and other clinical characteristics adjusted in each of the 8 PSM models. 95% confidence interval (CI) for the range of ATE is obtained through 500 bootstrap repetitions. Generalized linear modeling approach was used to model skewed costs. RESULTS: Following eight PSM algorithms were implemented: one-to-one, one-to-many (with replacement), 3 radius matching with caliper=0.01, 0.001 and 0.0001, kernel matching, and local linear regression matching. Robotic approach was found costlier with its costs varying between $16,713 and $17,522, while abdominal costs varied between $13,326 and $14,615. The minimum predicted cost difference was $2,812 (95%CI: $1,186; $4,437) while the maximum difference was $3,892 (95% CI: -$13, $7,796). As expected, the attrition in the matched sample size was highest in radius matching with caliper=0.0001. CONCLUSIONS:
The range for ATEs instead of a single ATE from a specific PSM algorithm provides a better understanding of minimum and maximum possible benefit of a medical intervention. 
CE3

ADVANTAGES OF BAYESIAN ADAPTIVE TRIALS FOR COMPARATIVE EFFECTIVENESS RESEARCH (CER): "RE-ADAPT"ING ALLHAT
OBJECTIVES:
Traditional randomized trials are the gold-standard for clinical research but may be long, expensive and, especially for CER, inefficient in providing evidence to practicing clinicians. We, the REsearch in ADAptive methods for Pragmatic Trials (RE-ADAPT) investigators sought to test efficiency gains in CER trials by redesigning, then re-executing ALLHAT using adaptive trial methodologies. METHODS: ALLHAT was a traditionally designed, large comparative trial looking at long-term cardiovascular outcomes with different classes of anti-hypertensive drugs compared with diuretics. We prospectively developed seven Bayesian adaptive designs incorporating combinations of early success/futility stopping, adaptive randomization, and arm dropping. Using only information available when ALLHAT was designed, we examined operating characteristics of the designs to evaluate clinical and economic efficiencies (e.g. shorter trials, greater allocation to superior treatments). One design was chosen a priorias the one we would have adopted for ALLHAT, including adaptive randomization with the potential for early stopping. The design was executed using the ALLHAT data, preserving accrual order and re-sampling patients when adaptive randomization called for additional patients in a given arm. RESULTS: ALLHAT enrolled 42,418 patients in four years, following patients for an additional four years and showed that none of the comparator treatments were superior to diuretics. The recommended adaptive design reached the same conclusion as the original ALLHAT trial but would have stopped nearly one year earlier. Also, the simulated trial randomized 28% more patients to calcium channel blockers, because it initially outperformed other arms during the accrual stage of the trial. CONCLUSIONS: CER trials are important to clinical research. However, conventional methods -even with early stopping rules as in ALLHAT -can be so time-consuming, that the clinical relevance of the study may be diminished before the results are published. Adaptive methods, tailored to CER, can be more efficient, and produce more timely evidence.
CE4 COMPARATIVE EFFECTIVENESS OF BIOLOGICS FOR THE INDUCTION OF CLINICAL RESPONSE AND REMISSION IN MODERATE TO SEVERE CROHN'S DISEASE: A NETWORK META-ANALYIS (NMA)
Tongbram V 1 , Szydlowski V 2 , Linnehan J 2 1 Oxford Outcomes, Morristown, NJ, USA, 2 Oxford Outcomes, Bethesda, MD, USA OBJECTIVES: In recent years, biologics, such as tumor necrosis factor inhibitors and integrin receptor antagonists have been shown to be effective in the treatment of moderate to severe Crohn's disease, and have changed the treatment paradigm. However, there are no direct or indirect comparisons establishing the relative efficacy of these treatments.The aim is to compare the effectiveness of approved biologics for the induction of clinical response and remission in moderate to severe Crohn's disease. METHODS: A systematic literature review searching EMBASE, MEDLINE, and the Cochrane Central Register of Controlled Trials was conducted to identify all randomized placebo controlled trials (RCT) of biologics in the treatment of moderate to severe Crohn's disease. Bayesian NMA models were developed to analyze clinical response (decrease in CDAI score >70 or 100) and remission (CDAI score <150) at the longest follow up. RESULTS: Eleven RCTs (3 natalizumab, 3 adalimumab, 4 certolizumab and 1 infliximab) were included. All biologics performed significantly better than placebo in inducing response and remission. In comparison to each other, we found that adalimumab and infliximab had higher odds-ratio (OR) for inducing clinical response as compared to certolizumab (OR 1.56, 95% CI 1.06-2.32 and OR 3.80, 95% CI 1.12-18.88 respectively). However, sensitivity analysis using response defined as decrease in CDAI >70 only, showed there was no significant difference between the biologics. Additionally, adalimumab had higher odds of inducing remission compared to natalizumab (OR 1.89, 95% CI 1.12-3.26) and certolizumab (OR 2.06, 95% CI 1.20-3.59). CONCLUSIONS: Our indirect treatment comparison confirms the findings of direct evidence that biologics are effective in the treatment of moderate to severe Crohn's disease. Our results on clinical response were found to be sensitive to the definition of clinical response used in the trials. We found that adalimumab performed better than natalizumab and certolizumab in inducing clinical remission.
